Stock PHVS PHARVARIS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
19.54 USD +7.54% Intraday chart for Pharvaris N.V. +4.72% -30.34%
04/06 Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses CI
09/05 Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating MT

Business Summary

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Number of employees: 83

Managers

Managers TitleAgeSince
Anne Lesage FOU
 Founder 63 30/15/30
Berndt A. E. Modig FOU
 Founder 65 30/15/30
Stefan Abele CTO
 Chief Tech/Sci/R&D Officer 55 15/11
Peng Lu CTO
 Chief Tech/Sci/R&D Officer 46 07/20/07
Annick Deschoolmeester HRO
 Human Resources Officer 51 01/22/01
Anna Nijdam AUD
 Comptroller/Controller/Auditor 42 01/20/01
Morgan Conn PRN
 Corporate Officer/Principal 42 01/17/01
Wim Souverijns PRN
 Corporate Officer/Principal 53 01/21/01

Members of the board

Members of the board TitleAgeSince
Berndt A. E. Modig FOU
 Founder 65 30/15/30
David Meeker CHM
 Chairman 69 01/21/01
Robert Glassman BRD
 Director/Board Member 62 01/21/01
Johannes G. C. P. Schikan FOU
 Founder 66 30/15/30
Margareta Elisabeth Björk BRD
 Director/Board Member 62 01/21/01
Viviane Monges BRD
 Director/Board Member 60 29/21/29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 53,816,707 32,830,017 ( 61.00 %) 0 61.00 %

Shareholders

NameEquities%Valuation
General Atlantic LLC
13.99 %
7,531,252 13.99 % 143 M $
Fidelity Management & Research Co. LLC
9.649 %
5,192,984 9.649 % 98 M $
venBio Partners LLC
7.970 %
4,289,304 7.970 % 81 M $
Foresite Capital Management LLC
7.505 %
4,038,842 7.505 % 77 M $
Viking Global Investors LP
6.788 %
3,653,310 6.788 % 69 M $
LSP Management Group BV
6.609 %
3,556,805 6.609 % 67 M $
Venrock Associates
6.310 %
3,395,606 6.310 % 64 M $
Bain Capital Life Sciences LP
6.138 %
3,303,381 6.138 % 63 M $
Commodore Capital LP
3.205 %
1,725,000 3.205 % 33 M $
Cormorant Asset Management LP
3.180 %
1,711,460 3.180 % 32 M $

Company contact information

Pharvaris NV

Emmy Noetherweg 2

2333 BK, Leiden

+

http://www.pharvaris.com
address Pharvaris N.V.(PHVS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
18.26 EUR
Average target price
30.79 EUR
Spread / Average Target
+68.64%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHARVARIS N.V. Stock Pharvaris N.V.
-30.34% 978M
MODERNA, INC. Stock Moderna, Inc.
+38.36% 52.5B
LONZA GROUP AG Stock Lonza Group AG
+36.73% 39.31B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.63% 39.01B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+25.46% 28.2B
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.57B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.44% 26.2B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.09% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.93% 12.62B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-5.30% 11.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PHVS Stock
  4. Company Pharvaris N.V.